EN
Human Antithrombin III
Native whole molecule
Product Overview, Sizes and Prices | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Proteins Synonyms: ATIII, Antithrombin, AT, Factor Xa inhibitor, Heparin cofactor Source: Human Plasma Purity: ≥ 95% by SDS-PAGE Physical State: Lyophilized from 50 mM Tris-HCl, pH 8.0, with 150 mM NaCl. Manufacturer: |
|
|||||||||||||||||
Athens Research & Technology
Produktdetails
Synonyms
ATIII, Antithrombin, AT, Factor Xa inhibitor, Heparin cofactor
Description of Human Antithrombin III
Human Antithrombin III is a 58 kDa protein. Antithrombin III (AT III), a glycoprotein serpin superfamily, circulates in plasma at 15 mg/100 mL and exhibits higher concentrations in plasma than serum due to thrombin complex formation during coagulation. This inhibitor primarily targets proteases in the coagulation cascade, including thrombin, factor Xa, IXa, and plasmin, through a two-step mechanism: initial docking via its reactive center loop (RCL) followed by irreversible covalent complex formation. Heparin enhances AT III activity >1000-fold by inducing conformational changes in the D-helix, which accelerates protease inhibition via allosteric activation (factor Xa/IXa) or bridging mechanisms (thrombin). Clinically, congenital AT III deficiency (1:500–5000 incidence) predisposes to venous thromboembolism (VTE), with 85% of carriers experiencing deep vein thrombosis (DVT) or pulmonary embolism (PE) by age 50. Acquired deficiencies arise from hepatic dysfunction, nephrotic syndrome, disseminated intravascular coagulation (DIC), or sepsis. Reduced AT III levels (<80% activity) correlate with hypercoagulability, postoperative thrombosis, and obstetric complications like preeclampsia. Therapeutically, human plasma-derived AT III concentrates are FDA-approved for hereditary deficiency management and perioperative prophylaxis in high-risk surgeries (e.g., cardiopulmonary bypass, liver transplantation). Emerging applications include adjunct therapy for COVID-19-associated coagulopathy and modulation of inflammatory signaling via endothelial syndecan-4 receptors. AT III monitoring guides anticoagulant dosing in heparin-resistant patients, while novel siRNA therapies targeting hepatic synthesis show promise for thromboprophylaxis.
Source
Human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests
Storage
For long term, store Human Antithrombin III at -20°C.
Applications
In Vitro Diagnostic, Coagulation/Fibrinolysis, Protease Inhibition, Rheumatoid Arthritis.
Citations/Publications
Huang, Y., et al., (2016), 'Blood compatibility of heparin-inspired, lactose containing, polyureas depends on the chemistry of the polymer backbone', Polym. Chem., 7: pp 3897. Available at: DOI: 10.1039/c6py00616g
NCBI: https://www.ncbi.nlm.nih.gov/protein/P01008
Shipped with ice packs
Gel Scan of Human Antithrombin III
| Fig. 1: SDS-PAGE Gel |
Usage: For research use only. Not for use in diagnostic or therapeutic procedures. Not for human use.
To buy Human Antithrombin III please click on the Shopping List Symbol right from the indicated price. This will add Human Antithrombin III to your Shopping List. You can then click on the button »Shopping List & Order Form« to ask for a quote. We will send you your quote as soon as possible. Our offer will include institutional discounts where applicable.
For business customers only. All prices are net prices (excluding VAT). Final prices in our quote will contain VAT plus shipping costs if applicable. For further information please go to our Shipping page.
Errors, changes and availability excepted.
Payment Methods
Paying by bank transfer
